Skip to content
  • Start
  • News
  • Video
  • Podcast
  • Event
  • Premium
    • Premium Content
    • VC Database
    • Company Database
    • Soft Funding & Grants
    • Job Database
  • About BioStock
Log in Subscribe
Home / Dasynoc

Dasynoc

Delay

FDA concerns delay Xspray Pharma's Dasynoc approval again

Xspray Pharma announces that the FDA's decision on market approval for Dasynoc is again delayed due to GMP complaints at an external...

Bioteknik
Premium
Per Andersson, CEO of Xspray Pharma, presents the company

BioStock Investor Pitch: Market next for Xspray Pharma

Xspray Pharma is in the final stages of preparations for...

Intervju
Video
Xspray at the end of market preparations

Capital injection to bring Xspray to market

Xspray Pharma is in the final stages of preparations...

Per Andersson, CEO of Xspray Pharma on capital raising

Xspray wants to launch better cancer drugs – CEO explains how

Xspray Pharma develops improved versions of already established...

Intervju
Video
Xspray Pharma CEO Per Andersson looks towards market launch

Xspray's CEO on the 2025 launch plan

Preparations are underway, market partner established and FDA application...

Intervju

BioStock

  • Start
  • News
  • Video
  • Podcast
  • Event
  • About BioStock
  • Privacy Policy
  • Terms and Conditions

Read BioStock's newsletter

Get industry news, company information and invitations to BioStock events directly in your inbox!

Val*
This field is used for validation purposes and should be left unchanged.
© 2025 Biostock